Analysis of participation degree of traditional Chinese medicine in lung malignant tumor cases from 30 hospitals in Beijing
LIU Liming1 CHENG Wei1,2 MAN Xiaowei1,2 ZHAO Liying1,2 YANG Hong1 XU Yue1 MA Lin1 JIANG Yan1,2
1.Beijing University of Chinese Medicine, Beijing 100029, China;
2.National Institute of Chinese Medicine Development and Strategy, Beijing University of Chinese Medicine, Beijing 100029, China
Abstract：Objective To explore the main factors that affect patients’ participation in traditional Chinese medicine, and to provide references for traditional Chinese medicine to participate in the treatment of lung malignant tumors. Methods Taking socio-demographic factors into consideration, a total of 30 hospitals in Beijing from January to December, 2016 were selected. The information of patients with lung malignant tumors was extracted from them, and the basic information, hospitalization status, and participation in traditional Chinese medicine were extracted. The factors affecting participation were analyzed statistically. Results A total of 12 163 hospitalized patients with lung malignant tumors were collected, and the effective number of cases was 12 099 cases. Among them, the proportion of male patients was higher than that of females, and the proportion of patients aged >60-80 years was the largest. The payment method was mainly urban employee basic medical insurance, and the proportion of patients in tertiary hospitals was much higher. In a secondary hospital, the average hospital stay was (11.62±9.39) days. The overall participation rate of traditional Chinese medicine in patients with lung malignant tumors was 69.30%. The single-factor analysis showed that the participation rate of traditional Chinese medicine was statistically significant in different genders, ages, payment methods, hospital levels and length of stay in hospital (P ＜ 0.05). The logistic regression results showed that payment method (OR = 1.864), hospital level (OR = 1.435) and hospital stay (OR = 1.047) were the main factors affecting the participation of traditional Chinese medicine in patients with lung malignant tumors (P ＜ 0.05). Conclusion The participation of traditional Chinese medicine in the treatment of lung malignant tumors can be further enhanced by rationally guiding the flow of medical treatment, exploring the characteristics of traditional Chinese medicine diagnosis and treatment methods, and improving the price system of traditional Chinese medicine services, which can reduce the cost burden of lung cancer while exerting the advantages of traditional Chinese medicine.
刘黎明1 程薇1,2 满晓玮1,2 赵丽颖1,2 杨红1 徐阅1 马琳1 . 北京市30所医院肺恶性肿瘤患者的中药参与度分析[J]. 中国医药导报, 2021, 18(14): 43-46.
LIU Liming1 CHENG Wei1,2 MAN Xiaowei1,2 ZHAO Liying1,2 YANG Hong1 XU Yue1 MA Lin1 JIANG Yan1,2. Analysis of participation degree of traditional Chinese medicine in lung malignant tumor cases from 30 hospitals in Beijing. 中国医药导报, 2021, 18(14): 43-46.
京公网安备 11010502046598号